Expression and prognostic relevance of activated extracellular-regulated kinases (ERK 1/2) in breast cancer

British Journal of Cancer

Volumn 92, Issue 12, 2005, Pages 2206-2215

  Milde Langosch, K ^a   Bamberger, A M ^a   Rieck, G ^a   Grund, D ^a   Hemminger, G ^a   Muller V ^a   Loning T ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Breast cancer; ERK1; ERK2; Phosphorylation; Prognosis

Indexed keywords

ESTROGEN RECEPTOR; GELATINASE B; INTERSTITIAL COLLAGENASE; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR PAI 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER INVASION; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; HUMANS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 22044438114     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602655     Document Type: Article

References (33)

1. Adeyinka A, Nui Y, Cherlet T, Snelle L, Watson PH, Murphy LC (2002) Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. Clin Cancer Res 8: 1747-1753
2. SAPK. Cancer Res 63: 1684-1695
3. Alblas J, Slager-Davidov R, Stteenbergh PH, Sussenbach JS, van den Burg B (1998) The role of MAP kinase in TPA-mediated cell cycle arrest of human breast cancer cells. Oncogene 16: 131-139
4. Amundadottir LT, Leder P (1998) Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes. Oncogene 16: 737-746
5. Bamberger A-M, Methner C, Lisboa BW, Städtler C, Schulte HM, Löning T, Milde-Langosch K (1999) Expression pattern of the AP-1 family in breast cancer: association of fosB expression with a well-differentiated, receptor-positive phenotype. Int J Cancer 84: 553-558
6. Barnes DM, Gillett CE (1998) Cyclin D1 in breast cancer. Breast Cancer Res Treat 52: 1-15
7. Blackball FH, Pintilie M, Michael M, Leighl N, Feld R, Tsao MS, Shepherd FA (2003) Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer. Clin Cancer Res 9: 2241-2247
8. Brummer O, Athar S, Riethdorf L, Löning T, Herbst H (1999) Matrix-metalloproteinases 1, 2 and 3 and their tissue inhibitors 1 and 2 in benign and malignant breast lesions: an in situ hybridization study. Virchows Arch 435: 566-573
9. Brunei A, Roux D, Lenormand P, Dowd S, Keyse S, Poussegur J (1999) Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry. EMBO J 18: 664-674
10. Collins P, Webb C (1999) Estrogen hits the surface. Nat Med 5: 1130-1131
11. Dublin E, Hanby A, Patel NK, Liebman R, Barnes D (2000) Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology. Am J Pathol 157: 1219-1227
12. Gee JM, Robertson JF, Ellis IO, Nicholson RI (2001) Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 95: 247-254
13. Givant-Horwitz V, Davidson B, Lazarovici P, Schaefer E, Nesland JM, Tropé CG, Reich R (2003) Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma effusions. Gynecol Oncol 91: 160-172
14. Griffiths MR, Black EJ, Culbert AA, Dickens M, Shaw PE, Gillespie DA, Tavaré JM (1998) Insulin-stimulated expression of c-fos, fra1 and c-jun accompanies the activation of the activator protein-1 (AP-1) transcriptional complex. Biochem J 335: 19-26
15. Gruda MC, Kovary K, Metz R, Bravo R (1994) Regulation of fra-1 and fra-2 phosphorylation differs during the cell cycle of fibroblasts and phosphorylation in vitro by MAP kinase affects DNA binding activity. Oncogene 9: 2537-2547
16. Handra-Luca A, Bilal H, Bertrand J-C, Fouret P (2003) Extra-cellular signal-related ERK-1/ERK-2 pathway activation in human salivary gland mucoepidermoid carcinoma. Am J Pathol 163: 957-967
17. Krueger JS, Keshamouni VG, Atanashkova N, Reddy KB (2001) Temporal and quantitative regulation of mitogen-activated protein kinase (MAPK) modulates cell motility and invasion. Oncogene 20: 4209-4218
18. Kupferman ME, Fini ME, Muller WJ, Weber R, Cheng Y, Muschel RJ (2000) Matrix metalloproteinase 9 promoter activity is induced coincident with invasion during tumor progression. Am J Pathol 157: 1777-1783
19. Malik SN, Brattain M, Ghosh PM, Troyer DA, Prihoda T, Bedolla R, Kreisberg JI (2002) Immunohistological demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 8: 1168-1171
20. Mechta-Grigoriou F, Gerald D, Yaniv M (2001) The mammalian Jun proteins: redundancy and specificity. Oncogene 20: 2378-2389
21. Milde-Langosch K, Bamberger AM, Methner C, Rieck G, Löning T (2000) Expression of cell cycle regulatory proteins Rb, p16/MTS1, p27/Kip1, p21/Waf1, cyclin D1 and cyclin E in breast cancer: correlations with expression of activating protein-1 family members. Int J Cancer 87:468-472
22. Milde-Langosch K, Kappes H, Riethdorf S, Löning T, Bamberger A-M (2003) FosB is highly expressed in normal mammary epithelia, but down-regulated in poorly differentiated breast carcinomas. Breast Cancer Res Treat 77: 265-275
23. Milde-Langosch K, Rôder H, Andritzky B, Asian B, Hemminger G, Brinkmann G, Bamberger CM, Löning T, Bamberger A-M (2004) The role of the transcription factors c-Fos, FosB, Fra-1 and Fra-2 in the invasion process of mammary carcinomas. Breast Cancer Res Treat 86: 139-152
24. Mueller H, Flury N, Eppenberger-Castori S, Kueng W, David F, Eppenberger U (2000) Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients. Int J Cancer 89: 384-388
25. Niemann C, Brinkmann V, Spitzer E, Hartmann G, Sachs M, Naundorf H, Birchmeier W (1998) Reconstitution of mammary gland development in vitro: requirement of c-met and c-erbB2 signaling for branching and alveolar morphogenesis. J Cell Biol 143: 533-545
26. Rosenberger SF, Finch JS, Gupta A, Bowden GT (1999) Extracellular signal-regulated kinase 1/2-mediated phosphorylation of JunD and FosB is required for ocadaic acid-induced activator protein 1 activation. J Biol Chem 274: 1124-1130
27. Salh B, Marotta A, Matthewson C, Ahluwalia M, Flint J, Owen D, Pelech S (1999) Investigation of the Mek-MAP kinase-Rsk pathway in human breast cancer. Anticancer Res 19: 731-740
28. Seddighzadeh M, Zhou JN, Kronenwett U, Shoshan MC, Auer G, Sten-Linder M, Wiman B, Linder S (1999) ERK signalling in metastatic human MDA-MB231 breast carcinoma cells is adapted to obtain high urokinase expression and rapid cell proliferation. Clin Exp Metast 17: 649-654
29. Shen Q, Brown PH (2003) Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathways. J Mammary Gland Biol Neoplasia 8: 45-73
30. Sivaraman VS, Wang H-Y, Nuovo GJ, Malbon CC (1997) Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 99: 1478-1483
31. Tsurumi C, Ishida N, Tamura T, Kakizuka A, Nishida E, Okumura E, Kishimoto T, Inagaki M, Okazaki K, Sagata N, Ichihara H, Tanaka K (1995) Degradation of c-fos by the 26S proteasome is accelerated by c-jun and multiple protein kinases. Mol Cell Biol 15: 5682-5687
32. Wang F, Hansen RK, Radisky D, Yoneda T, Barcellos-Hoff MH, Petersen OW, Turley EA, Bissell MJ (2002) Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts. J Natl Cancer Inst 94: 1494-1503
33. Whitmarsh AJ, Davis RJ (1996) Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med 74: 589-607